Padcev 20 mg powder for concentrate for solution for infusion

C5701002/SGN22E-002 - A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer

Multicenter, open label, single arm, phase II study to assess the efficay and safety of enfortumab-vedotin (EV) as a single agent in patients with advanced Neuroendocrine Carcinomas (NEC) refractory or ineligible to platinum-containing chemotherapy

A Phase II, Open-Label, Multicenter, Non-Randomized Study Of The Efficacy And‬ Safety Of Enfortumab Vedotin In Combination With Pembrolizumab Previously Treated‬ Advanced Melanoma‬

A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA)